Naftopidil hydrochloride

Research use only, not for human use.

Naftopidil hydrochloride is a selective alpha1-adrenoceptor antagonist with Ki of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-adrenoceptor, α1b-adrenoceptor and α1d-adrenoceptor, respectively.

Naftopidil hydrochloride is a selective alpha1-adrenoceptor antagonist with Ki of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-adrenoceptor, α1b-adrenoceptor and α1d-adrenoceptor, respectively. Naftopidil hydrochloride has antiproliferative effects.

Naftopidil hydrochloride suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.Naftopidil hydrochloride (10 μM for PCa cells, 0.1-10 μM for PrSC; 3 days) shows growth inhibitory effects on PCa cells and PrSC.Naftopidil hydrochloride (50 μM for E9 cells, 25 μM for PrSC; 48 hours) increases the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC. Cell Proliferation Assay Cell Line:PCa cells, PrSC Concentration:10 μM (PCa cells); 0.1 μM, 1 μM, 10 μM (PrSC) Incubation Time:3 days Result:Exhibited growth inhibitory effects on PCa cells and PrSC in dose-dependent manners.Western Blot Analysis Cell Line:PCa cells, PrSC Concentration:50 μM (E9 cells), 25 μM (PrSC)Incubation Time:48 hours Result:Increased the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC.

Naftopidil hydrochloride (10 mg/kg; p.o; daily; for 28 days) decreases microvessel density (MVD) in E9+PrSC tumors mice model. Animal Model:Male athymic mice(7-8 weeks), with E9+PrSC xenograft Dosage:10 mg/kg Administration:Oral administration, daily, for 28 days Result:Decreased tumor weights.

KT-611 hydrochloride | BM-15275 hydrochloride | 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-

Apoptosis

Adenosine Receptor

α1-adrenoceptor

——

——

1164469-60-6

428.95

C24H29ClN2O3

>98% (HPLC)

——

OC(COC1=C2C=CC=CC2=CC=C1)CN3CCN(C4=CC=CC=C4OC)CC3.[H]Cl

——

(-20℃)

With Ice Pack

≥ 2 years